Richard Scott Struthers - 02 Nov 2023 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
02 Nov 2023
Net transactions value
-$4,255,440
Form type
4
Filing time
06 Nov 2023, 18:02:02 UTC
Previous filing
16 Aug 2023
Next filing
13 Nov 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $8,519 +918 +0.68% $9.28 136,440 02 Nov 2023 Direct
transaction CRNX Common Stock Sale $27,494 -918 -0.67% $29.95 135,522 02 Nov 2023 Direct
transaction CRNX Common Stock Options Exercise $1,847,481 +199,082 +147% $9.28 334,604 03 Nov 2023 Direct
transaction CRNX Common Stock Sale $6,083,946 -199,082 -59% $30.56 135,522 03 Nov 2023 Direct F1
holding CRNX Common Stock 630,805 02 Nov 2023 By Family Trust 1
holding CRNX Common Stock 1,000 02 Nov 2023 By Spouse
holding CRNX Common Stock 90,000 02 Nov 2023 By Family Trust 2
holding CRNX Common Stock 90,000 02 Nov 2023 By Family Trust 3
holding CRNX Common Stock 90,000 02 Nov 2023 By Family Trust 4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -918 -0.25% $0.000000 363,823 02 Nov 2023 Common Stock 918 $9.28 Direct F2
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -199,082 -55% $0.000000 164,741 03 Nov 2023 Common Stock 199,082 $9.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a weighted average sales price of $30.56 per share. The range of sales prices on the transaction date was $29.95 to $31.37 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.